| DB ID | MyCo_5615 |
| Title | Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children |
| Year | 2019 |
| PMID | 31506548 |
| Fungal Diseases involved | Invasive mold infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | For a retrospective study on children and adolescents suffering from CNS IMD, patients were identified by recollection of the local investigators. The clinical details and patients’ outcome have been reported elsewhere as part of a larger cohort. In this analysis, children and adolescents <18 years were included if they (1) received chemotherapy for a malignant disease or underwent allogeneic hematopoietic stem cell transplantation (HSCT), (2) had been diagnosed with proven or probable CNS IMD between 2007 and 2016 and (3) GM and/or PCR was assessed in CNS samples. Pediatric patients with possible CNS IMD were not included in the analysis. As data on the value of biomarkers in the cnS are scarce, in particular in children, we retrospectively analyzed the performance of galactomannan (GM) and PCR assays in CNS samples of 15 children with proven and probable CNS IMD and of 32 immunocompromised children without fungal infection. |
| Cohort No. | 15 Patients, 32 Control |
| Age Group | <18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive mold disease (IMD) of the central nervous system (CNS) is a particularly severe infectious complication in immunocompromised patients, and despite the availability of potent antifungal compounds, mortality rates remain unacceptably high. Although Aspergillus spp is the most frequent cause of CNS IMD, other pathogens such as Fusarium spp or the mucormycetes (e.g., Rhizopus, Mucor, Rhizomucor, Lichtheimia) also have to be considered. The difficulty to establish a microbiological diagnosis of CNS IMD might explain that data on their epidemiology are scarce, in particular in the pediatric setting. However, early and adequate diagnosis of CNS IMD has important implications on treatment, as therapeutic strategies of CNS IMD may differ from IMD of other organs with regard to the choice and dosage of the antifungal compound and/or surgery. |
| Technique | PCR |
| Analysis Method | qRT-PCR |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad, Hercules, CA, USA) |
| Assay Data | None |
| Validation Techniques used | qRT-PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
